TY - JOUR
T1 - Epigenetic reprogramming in metabolic disorders
T2 - nutritional factors and beyond
AU - Cheng, Zhiyong
AU - Zheng, Louise
AU - Almeida, Fabio A.
N1 - Funding Information:
This work was funded in part by USDA National Institute of Food and Agriculture Hatch Project 1007334 (Zhiyong Cheng) and NIH Grant 5R18DK091811-02 (Fabio A. Almeida).
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/4
Y1 - 2018/4
N2 - Environmental factors (e.g., malnutrition and physical inactivity) contribute largely to metabolic disorders including obesity, type 2 diabetes, cardiometabolic disease and nonalcoholic fatty liver diseases. The abnormalities in metabolic activity and pathways have been increasingly associated with altered DNA methylation, histone modification and noncoding RNAs, whereas lifestyle interventions targeting diet and physical activity can reverse the epigenetic and metabolic changes. Here we review recent evidence primarily from human studies that links DNA methylation reprogramming to metabolic derangements or improvements, with a focus on cross-tissue (e.g., the liver, skeletal muscle, pancreas, adipose tissue and blood samples) epigenetic markers, mechanistic mediators of the epigenetic reprogramming, and the potential of using epigenetic traits to predict disease risk and intervention response. The challenges in epigenetic studies addressing the mechanisms of metabolic diseases and future directions are also discussed and prospected.
AB - Environmental factors (e.g., malnutrition and physical inactivity) contribute largely to metabolic disorders including obesity, type 2 diabetes, cardiometabolic disease and nonalcoholic fatty liver diseases. The abnormalities in metabolic activity and pathways have been increasingly associated with altered DNA methylation, histone modification and noncoding RNAs, whereas lifestyle interventions targeting diet and physical activity can reverse the epigenetic and metabolic changes. Here we review recent evidence primarily from human studies that links DNA methylation reprogramming to metabolic derangements or improvements, with a focus on cross-tissue (e.g., the liver, skeletal muscle, pancreas, adipose tissue and blood samples) epigenetic markers, mechanistic mediators of the epigenetic reprogramming, and the potential of using epigenetic traits to predict disease risk and intervention response. The challenges in epigenetic studies addressing the mechanisms of metabolic diseases and future directions are also discussed and prospected.
KW - DNA methylation
KW - Epigenetic marker
KW - Intervention
KW - Metabolic disorders
KW - Reprogramming
UR - http://www.scopus.com/inward/record.url?scp=85034047840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034047840&partnerID=8YFLogxK
U2 - 10.1016/j.jnutbio.2017.10.004
DO - 10.1016/j.jnutbio.2017.10.004
M3 - Review article
C2 - 29154162
AN - SCOPUS:85034047840
VL - 54
SP - 1
EP - 10
JO - Nutrition Reports International
JF - Nutrition Reports International
SN - 0955-2863
ER -